We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

AI-Enabled Chest X-Ray Solution Identifies Heart Failure Risk

By MedImaging International staff writers
Posted on 02 Oct 2023
Print article
Image: The qXR-CTR chest X-ray solution has received FDA clearance as a potential indicator for identifying heart failure risk (Photo courtesy of Qure.ai)
Image: The qXR-CTR chest X-ray solution has received FDA clearance as a potential indicator for identifying heart failure risk (Photo courtesy of Qure.ai)

Heart failure is often a difficult condition to diagnose correctly because its symptoms can be quite vague. Now, a novel chest X-ray algorithm can screen for telltale signs of heart failure, such as an enlarged cardiothoracic ratio (CTR) and fluid in the lungs, along with other indicators visible on X-rays. This development represents a significant leap forward in the fields of medical imaging and heart care, offering a new method for early detection of heart failure via automated analysis of chest X-rays.

The qXR-CTR artificial intelligence (AI)-enabled chest X-ray solution from Qure.ai Technologies (New York, NY, USA) is an AI-powered solution designed to assist doctors in both hospital and clinic settings by automating the measurement of the CTR on chest X-rays. Specifically, it calculates the ratio of the maximum transverse diameter of the heart to the maximum inner transverse diameter of the thoracic cavity, providing the most accurate indicator of cardiomegaly on plain film. By employing advanced AI algorithms, the technology offers quick and accurate results, saving valuable time for healthcare professionals and enhancing the reliability of diagnoses.

Qure.ai has now received FDA clearance for measuring the CTR utilizing qXR-CTR, marking the company's 12th FDA-cleared algorithm. Qure.ai’s previous FDA-cleared findings include endotracheal tube location, tracheostomy tube location, pneumothorax, and pleural effusion identification for CXR; qER for intracranial hemorrhage detection on head CT scans, and qER Quant for quantifying serious abnormalities on head CT scans.

"We are delighted to receive FDA clearance for qXR-CTR,” said Prashant Warier, Co-Founder and CEO at Qure.ai. “This cutting-edge algorithm enhances the accuracy and efficiency of CTR assessment and empowers healthcare professionals with a valuable tool to diagnose and monitor risk of heart failure. This achievement reaches an industry record for the greatest number of FDA-cleared findings on CXR scans, demonstrating Qure.ai's commitment to advancing better patient outcomes through AI-driven solutions."

Related Links:
Qure.ai Technologies

Gold Member
Solid State Kv/Dose Multi-Sensor
Mobile Digital C-arm X-Ray System
Silver Member
Radiographic Positioning Equipment
2-Step Multiview Positioning Platform
Powered Echocardiography Imaging/Ultrasound Table
Powered Echo

Print article



view channel
Image: The artificial intelligence model outperformed clinical tests at predicting the progress of Alzheimer’s disease (Photo courtesy of 123RF)

AI Outperforms Clinical Tests at Predicting Alzheimer’s Progress from MRI Scans

Dementia is a major global health challenge, impacting over 55 million individuals worldwide and costing approximately USD 820 billion annually. Projections indicate that the number of cases will nearly... Read more


view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

General/Advanced Imaging

view channel
Image: The NeuroLF ultra-compact brain Positron Emission Tomography (PET) scanner (Photo courtesy of Positrigo)

Breakthrough Brain PET System Aids Diagnosis of Neurological Disorders

Alzheimer's disease (AD) is the most prevalent type of dementia, representing approximately 70% of all dementia cases in individuals over 60 years of age. As of 2020, there were more than 55 million people... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.